The government quashes a nasty stunt used by drug makers to keep prescription prices high
Most of the efforts out of Washington to fight rising drug prices amount to all-talk-no-action. But there's one government campaign that has worked - and that the government just expanded.
This is the government's attack on so-called pay-to-delay schemes, in which the marketer of a brand-name drug pays off generic drug makers to keep their competing products off the shelves, sometimes for years.
The Federal Trade Commission, which has scored a string of courtroom victories
